Eye infection breakthrough: new trial tests antivirals to save sight
NCT ID NCT03586284
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two antiviral medicines (oral valganciclovir and topical ganciclovir 2%) against a placebo for treating CMV-related inflammation in the front of the eye. The goal was to see which approach better controls the infection and reduces complications like pain, glaucoma, and vision loss. The trial enrolled 51 adults with confirmed CMV anterior uveitis and measured changes in viral load and eye inflammation over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS ANTERIOR UVEITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chiang Mai University
Chiang Mai, Thailand
-
Chulalongkorn University
Bangkok, Thailand
-
Khon Kaen University
Khon Kaen, Thailand
-
Proctor Foundation, UCSF
San Francisco, California, 94158, United States